Khandan Keyomarsi

17PUBLICATIONS
78CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jan 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction.

Linjie Luo, Yan Wang, Tuyen Bui

|Dec 24, 2025
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts.

Xiao-Ting Jiang, Mei-Kuang Chen, Jiwang Lee

|Jan 26, 2025
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.

Akshara Singareeka Raghavendra, Nicole M Kettner, Danielle Kwiatkowski

|Aug 26, 2024
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.

Mi Li, Amriti R Lulla, Yan Wang

|Feb 10, 2024
Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.

Taiwo Adesoye, Debasish Tripathy, Kelly K Hunt

|Jan 03, 2024
Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance.

Hyemin Lee, Amber Horbath, Lavanya Kondiparthi

Pageof 3

Frequent Collaborators

8 joint publications

Kelly K Hunt

6 joint publications

Yan Wang

5 joint publications

Mi Li

4 joint publications

Nicole M Kettner